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The Complexity of Stenting in
Bifurcation Coronary Lesions*Ran Kornowski, MD
Petach Tikva, Israel
The treatment of bifurcation lesions remain a technical
challenge. Bifurcation lesions represent up to 20% of coro-
nary stenosis that demands percutaneous coronary inter-
vention (1). They are associated with augmented long-term
risk for reintervention and stent thrombosis compared with
nonbranching lesions (2). Drug-eluting stents (DES) have
demonstrated a marked reduction in restenosis, resulting in
improved clinical outcomes when compared with bare-metal
stents (3,4). Nonetheless, uncertainty remains regarding the
long-term safety of DES implantation in bifurcation lesions.
In particular, increased incidence of stent thrombosis and/or
ischemic coronary events has been reported (5).See page 687The treatment of bifurcation lesions often pose a dilemma
to the operator. The dilemma is whether to use 1 or 2 stents
(6). This is a strategic decision rather than a technical one, as it
may alter the course of the intervention and could affect the
patient’s long-term prognosis. Current practice in bifurcation
lesions involves, if possible, a stenting procedure of the main
branch with an option for balloon dilation or a bailout stenting
of the side branch in case of a threatened need (e.g., “provi-
sional” technique). However, in lesions with a large side branch
and with severe obstructive ostial atherosclerotic involvement,
there is a tendency to use a 2-stent strategy up front (7).
It should be appreciated that any comparison between
a single- versus double-stent approach might be subjected to
inherent bias, as the 2-stent technique is aimed at solving
a more complex bifurcation milieu (8). Thus, a sophisticated
procedure shouldbedesigned to treatmore complex bifurcation
disease. This is why the comparison between the 2 strategies is
somewhat tricky, especiallywhen derived fromnonrandomized
registries or using case-selective randomized studies.*Editorials published in JACC: Cardiovascular Interventions reﬂect the views of the
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the contents of this paper to disclose.In this volume, Zimarino et al. (9) have presented their
important cross-design meta-analysis of 5 randomized
controlled trials and 7 observational studies of bifurcation
stenting. The analysis involves 6,961 patients and tests the
hypothesis that increased myocardial infarction (MI) after
the routine placement of double DES (n ¼ 1,868) compared
with single DES (n ¼ 5,093) is caused by DES thrombosis.
The investigators observed that, compared with single DES,
double DES was associated with increased risks of stent
thrombosis (risk ratio [RR]: 2.31, 95% conﬁdence interval
[CI]: 1.33 to 4.03) and MI (RR: 1.86, 95% CI: 1.34 to
2.60); however, mortality (RR: 1.18, 95% CI: 0.85 to 1.65)
and target vessel revascularization (RR: 1.02, 95% CI: 0.80
to 1.30) were similar between the 2 strategies. The risk of
MI and DES thrombosis were associated (p ¼ 0.040). In
this report, the investigators conﬁrmed the hypothesis that
was tested by the analysis.
For such a meta-analysis to be reliable and conclusive, it
must fulﬁll certain key methods criteria that involve well-
deﬁned objectives, precise deﬁnitions of clinical variables
and outcomes, and a well-documented study identiﬁcation
and selection strategy (10). It must also evaluate potential
bias and contain a description and evaluation of heteroge-
neity and sensitivity analysis. I think that the current work
by Zimarino et al. (9) meets most of the key methods
standards required for a conclusive meta-analysis. My main
concern is that the selection of the trials was heterogeneous,
and the data seems somewhat difﬁcult to pool. For example,
the ARTS II (Arterial Revascularization Therapies Study
Part II) (11) had very little to do with bifurcation lesion
techniques, as it involved the treatment of patients with
multivessel disease. In addition, most trials quoted by
Zimarino et al. (9) were actually retrospective registries, and
the potential for selection bias in the treatment approach
could not be ruled out. Also, the mentioned studies included
the use of the ﬁrst-generation DES, which is associated with
greater long-term thrombogenicity than are contemporary
DES platforms (12). Finally, the background pathology does
not involve only the stent technique. It also relates to the
individual patient characteristics and the bifurcation lesion
involved. In other words, one might assume that there are
unidentiﬁable reasons why some patients were treated using
>1 stent. The use of >1 stent could be a surrogate marker
for more complex atherosclerotic disease or for more
advanced bifurcation involvement that may lead to increased
thrombotic complications.
Despite these limitations, I share the investigators’ view
and conclusions regarding the topic at hand. It is probably
the clinical experiences and impression obtained by multiple
interventional cardiology centers and operators. It is reas-
suring that whenever needed, long-term mortality has not
been augmented by using the double- versus single-stenting
technique, despite a signiﬁcant trend toward more target
vessel–related ischemic events. What is the take-home
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697message for the interventional cardiologist who is confronted
with bifurcation lesions in daily practice? And how could
this message alter the treatment strategy? I presume that the
answer is somewhat unclear. Optimal treatment is about
obtaining the best results using the least amount of unnec-
essary complexity. However, when managing bifurcation
lesions, the treatment strategy is often dictated by lesion
complexity rather than the operator’s desired preferences.
Perhaps the most relevant part of the story relates to the role
of antithrombotic treatment after intervention. Because
there are no available data regarding the potential implica-
tions of a single- versus double-stent selection on the mode
and/or duration of antiplatelet pharmacotherapy, future
studies should assess whether more potent and/or prolonged
antiplatelet therapies might reduce the risk of DES
thrombosis in the setting of complex bifurcation lesions.
Finally, contemporary treatments of complex bifurcations
are still evolving. Novel stents and dedicated devices are
already in use in many parts of the world. Thus, the current
meta-analysis by Zimarino et al. (9) reﬂects a clinical reality
that may change over time.
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